TriangleNCT00549848 · OUTCOME
Probability of Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years
What was measured
To estimate the overall survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV.
Analysis population: All eligible patients entered on TOTXVI will be included in these analyses, as appropriate. Infants will be excluded from the Total XVI for comparisons with TOTXV as only children at least one year of age at diagnosis were treated on Total XV.
Groups in this outcome
TOTXVI PEG 3500
Patients randomized on the first day of continuation phase to receive 3500 units/m\^2 dose of PEG-asparaginase
TOTXVI PEG 2500
Patients randomized on the first day of continuation phase to receive 2,500 units/m\^2 dose of PEG-asparaginase
TOTVI Not Randomized
Patients who came off study prior to randomization
All Eligible Patients in TOTXV
All eligible children with ALL who are treated with risk-directed therapy.
| Group | Source count |
|---|---|
| TOTXVI PEG 3500 | 201 |
| TOTXVI PEG 2500 | 205 |
| TOTVI Not Randomized | 180 |
| All Eligible Patients in TOTXV | 498 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| TOTXVI PEG 3500 | 97.5 | Not reported | 95.3 | 99.7 | Not reported |
| TOTXVI PEG 2500 | 95.6 | Not reported | 92.7 | 98.5 | Not reported |
| TOTVI Not Randomized | 90.8 | Not reported | 84.7 | 96.9 | Not reported |
| All Eligible Patients in TOTXV | 93.5 | Not reported | 91.3 | 95.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 95.3
- upper Limit
- 99.7
- value
- 97.5
- group Id
- OG001
- lower Limit
- 92.7
- upper Limit
- 98.5
- value
- 95.6
- group Id
- OG002
- lower Limit
- 84.7
- upper Limit
- 96.9
- value
- 90.8
- group Id
- OG003
- lower Limit
- 91.3
- upper Limit
- 95.7
- value
- 93.5
- denoms
- counts
- group Id
- OG000
- value
- 201
- group Id
- OG001
- value
- 205
- group Id
- OG002
- value
- 180
- group Id
- OG003
- value
- 498
- units
- Participants
- description
- To estimate the overall survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients randomized on the first day of continuation phase to receive 3500 units/m\^2 dose of PEG-asparaginase
- id
- OG000
- title
- TOTXVI PEG 3500
- description
- Patients randomized on the first day of continuation phase to receive 2,500 units/m\^2 dose of PEG-asparaginase
- id
- OG001
- title
- TOTXVI PEG 2500
- description
- Patients who came off study prior to randomization
- id
- OG002
- title
- TOTVI Not Randomized
- description
- All eligible children with ALL who are treated with risk-directed therapy.
- id
- OG003
- title
- All Eligible Patients in TOTXV
- param Type
- NUMBER
- population Description
- All eligible patients entered on TOTXVI will be included in these analyses, as appropriate. Infants will be excluded from the Total XVI for comparisons with TOTXV as only children at least one year of age at diagnosis were treated on Total XV.
- reporting Status
- POSTED
- time Frame
- For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years
- title
- Probability of Overall Survival
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice